中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 1
Jan.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(1): 52-56

Liver histopathological features of HBeAg-negative patients in the indeterminate phase of low-viral-load chronic hepatitis B virus infection

DOI: 10.12449/JCH250108

  • Department of Infectious Diseases，Yan’an Key Clinical Laboratory of Infectious Diseases，Affiliated Hospital of Yan’an University，Yan’an，Shaanxi 716000，China

Research funding:

Yan’an City Science and Technology Research and Development Plan (2014HM-09)

More Information
  • Corresponding author: LIU Na， liunamei1984@163.com （ORCID： 0000-0002-9842-0112）
  • Received Date: 2024-05-06
  • Accepted Date: 2024-09-09
  • Published Date: 2025-01-25
    Abstract
  •   Objective  To investigate the liver histopathological features of HBeAg-negative patients in the indeterminate phase of low-viral-load chronic hepatitis B virus （HBV） infection.  Methods  A total of 271 patients with low-viral-load HBeAg-negative chronic HBV infection who underwent liver biopsy in Department of Infectious Diseases， Affiliated Hospital of Yan’an University， from September 2013 to June 2021 were enrolled as subjects， and the degree of liver injury was compared between patients based on age， sex， presence or absence of the family history of hepatitis B， HBsAg， and alanine aminotransferase （ALT） level. The chi-square test was used for comparison of categorical data between two groups.  Results  Among the 271 patients with HBeAg-negative chronic HBV infection， 86 patients （31.73%） grade≥A2 liver inflammatory activity， 72 （26.57%） had a liver fibrosis stage of ive， and 112 （41.33%） had moderate or severe liver histological injury. The proportion of patients with grade≥A2 liver inflammatory activity in the patients with ALT>20 U/L was significantly higher than that in the patients with ALT≤20 U/L （χ2=3.938， P=0.047）. There were no significant differences in the proportion of patients with grade≥A2 liver inflammatory activity between the patients with different ages， sexes， family history of hepatitis B， HBsAg levels （all P>0.05），there were no significant differences in the proportion of patients with a liver fibrosis stage of ≥F2 between the patients with different ages， sexes， family history of hepatitis B， HBsAg， and ALT levels （all P>0.05）， and the stratified analysis of patients aged≤30 years and patients without the family history of hepatitis B showed no statistical significance between groups （all P>0.05）. There was no significant difference in the degree of liver histological injury between the patients with different ages， sexes， family history of hepatitis B， HBsAg， and ALT levels （all P>0.05）.  Conclusion  Significant liver injury is observed in more than 40% of the patients with low-viral-load HBeAg-negative chronic HBV infection， and there is no significant difference in the degree of liver histological injury between the patients with different ages， sexes， family history of hepatitis B， HBsAg， and ALT levels. Even for the patients aged≤30 years who deny the family history of hepatitis B， there is still a considerable proportion of patients with liver injury， which should be taken seriously by clinicians.

     

    • FullText(HTML)
  • loading
    • References(14)
  • [1]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(2022 version)[J]. Chin J Infect Dis, 2023, 4( 1): 3- 28. DOI: 10.3760/cma.j.cn11365-20230220-00050.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050.
    [2]
    YAO K, LIU J, WANG J, et al. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone[J]. J Viral Hepat, 2021, 28( 7): 1025- 1033. DOI: 10.1111/jvh.13511.
    [3]
    ZHAN J, WANG J, ZHANG Z, et al. Noninvasive diagnosis of significant liver inflammation in patients with chronic hepatitis B in the indeterminate phase[J]. Virulence, 2023, 14( 1): 2268497. DOI: 10.1080/21505594.2023.2268497.
    [4]
    HUANG DQ, LI X, LE MH, et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase[J]. Clin Gastroenterol Hepatol, 2022, 20( 8): 1803- 1812. e 5. DOI: 10.1016/j.cgh.2021.01.019.
    [5]
    HUANG DQ, TRAN A, YEH ML, et al. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase[J]. Hepatology, 2023, 78( 5): 1558- 1568. DOI: 10.1097/HEP.0000000000000459.
    [6]
    MARTIN P, NGUYEN MH, DIETERICH DT, et al. Treatment algorithm for managing chronic hepatitis B virus infection in the United States: 2021 update[J]. Clin Gastroenterol Hepatol, 2022, 20( 8): 1766- 1775. DOI: 10.1016/j.cgh.2021.07.036.
    [7]
    KAO JH, HU TH, JIA J, et al. East Asia expert opinion on treatment initiation for chronic hepatitis B[J]. Aliment Pharmacol Ther, 2020, 52( 10): 1540- 1550. DOI: 10.1111/apt.16097.
    [8]
    WEI S, XIE Q, LIAO G, et al. Patients with chronic hepatitis B who have persistently normal alanine aminotransferase or aged<30 years may exhibit significant histologic damage[J]. BMC Gastroenterol, 2024, 24( 1): 120. DOI: 10.1186/s12876-024-03208-9.
    [9]
    RUGGIERI A, GAGLIARDI MC, ANTICOLI S. Sex-dependent outcome of hepatitis B and C viruses infections: synergy of sex hormones and immune responses?[J]. Front Immunol, 2018, 9: 2302. DOI: 10.3389/fimmu.2018.02302.
    [10]
    NING HB, JIN HM, LI K, et al. Liver pathological characteristics and the value of serum non-invasive diagnostic model in chronic hepatitis B patients with normal alanine aminotransferase and negative hepatitis B antigen[J]. Chin J Infect Dis, 2022, 40( 12): 729- 734. DOI: 103760/cma.j.cn311365-20220321-0009.

    宁会彬, 靳慧鸣, 李宽, 等. 丙氨酸转氨酶正常的乙型肝炎e抗原阴性慢性乙型肝炎患者的肝脏病理特征及血清学无创诊断模型价值分析[J]. 中华传染病杂志, 2022, 40( 12): 729- 734. DOI: 10.3760/cma.j.cn311365-20220321-0009.
    [11]
    SONNEVELD MJ, BROUWER WP, HANSEN BE, et al. Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis[J]. Aliment Pharmacol Ther, 2020, 52( 8): 1399- 1406. DOI: 10.1111/apt.16067.
    [12]
    GAO Y, WANG M, LIU X. Noninvasive serum markers for predicting significant liver histopathology in HBeAg-negative chronic HBV-infected patients with normal alanine aminotransferase[J]. Microbiol Spectr, 2024, 12( 4): e0394123. DOI: 10.1128/spectrum.03941-23.
    [13]
    Chinese Society of Hepatology, Chinese Medical Association. Expert opinion on expanding anti-HBV treatment for chronic hepatitis B[J]. Chin J Hepatol, 2022, 30( 2): 131- 136. DOI: 10.3760/cma.j.cn501113-20220209-00060.

    中华医学会肝病学分会. 扩大慢性乙型肝炎抗病毒治疗的专家意见[J]. 中华肝脏病杂志, 2022, 30( 2): 131- 136. DOI: 10.3760/cma.j.cn501113-20220209-00060.
    [14]
    DUAN M, CHI X, XIAO H, et al. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B[J]. Hepatol Int, 2021, 15( 2): 318- 327. DOI: 10.1007/s12072-021-10153-2.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (111) PDF downloads(20) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return